Illumina (ILMN -7.88%), a global leader in DNA sequencing and genomics, released its second quarter results on July 31, 2025, for the fiscal 2025 period. The results were notable for beating analyst expectations on both non-GAAP EPS and GAAP revenue. Non-GAAP earnings per share reached $1.19, compared to the$1.01 non-GAAP consensus. Revenue (GAAP) landed at $1.06 billion, just ahead of the$1.05 billion estimate—though down 3% from the prior year. Management also provided a modestly improved full-year outl ...